Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 295

1.

[Ketamine's antidepressant effect: literature review on clinical use].

De Maricourt P, Jay T, Goncalvès P, Lôo H, Gaillard R.

Encephale. 2014 Feb;40(1):15-23. doi: 10.1016/j.encep.2013.09.001. Epub 2014 Jan 14. Review. French.

PMID:
24434008
2.

A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.

Naughton M, Clarke G, O'Leary OF, Cryan JF, Dinan TG.

J Affect Disord. 2014 Mar;156:24-35. doi: 10.1016/j.jad.2013.11.014. Epub 2013 Dec 10. Review.

PMID:
24388038
3.

[Ketamine's antidepressant effect: focus on ketamine mechanisms of action].

De Maricourt P, Jay T, Goncalvès P, Lôo H, Gaillard R.

Encephale. 2014 Feb;40(1):48-55. doi: 10.1016/j.encep.2013.09.002. Epub 2014 Jan 13. Review. French.

PMID:
24434007
4.

Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.

Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Furey ML, Zarate CA Jr.

Int J Neuropsychopharmacol. 2014 Oct 31;18(1). pii: pyu039. doi: 10.1093/ijnp/pyu039.

5.

Ketamine administration in depressive disorders: a systematic review and meta-analysis.

Fond G, Loundou A, Rabu C, Macgregor A, Lançon C, Brittner M, Micoulaud-Franchi JA, Richieri R, Courtet P, Abbar M, Roger M, Leboyer M, Boyer L.

Psychopharmacology (Berl). 2014 Sep;231(18):3663-76. doi: 10.1007/s00213-014-3664-5. Epub 2014 Jul 20. Review.

PMID:
25038867
6.

What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.

Strasburger SE, Bhimani PM, Kaabe JH, Krysiak JT, Nanchanatt DL, Nguyen TN, Pough KA, Prince TA, Ramsey NS, Savsani KH, Scandlen L, Cavaretta MJ, Raffa RB.

J Clin Pharm Ther. 2017 Apr;42(2):147-154. doi: 10.1111/jcpt.12497. Epub 2017 Jan 22. Review.

PMID:
28111761
7.

[Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy].

Gosek P, Chojnacka M, Bieńkowski P, Swiecicki Ł.

Psychiatr Pol. 2014 Jan-Feb;48(1):49-58. Polish.

PMID:
24946434
8.

Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.

Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T.

Neuro Endocrinol Lett. 2013;34(4):287-93.

PMID:
23803871
9.

Ketamine for the treatment of depression.

Howland RH.

J Psychosoc Nurs Ment Health Serv. 2013 Jan;51(1):11-4.

PMID:
23413455
10.

Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.

Diamond PR, Farmery AD, Atkinson S, Haldar J, Williams N, Cowen PJ, Geddes JR, McShane R.

J Psychopharmacol. 2014 Jun;28(6):536-44. doi: 10.1177/0269881114527361. Epub 2014 Apr 3.

PMID:
24699062
11.

Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.

Shiroma PR, Johns B, Kuskowski M, Wels J, Thuras P, Albott CS, Lim KO.

J Affect Disord. 2014 Feb;155:123-9. doi: 10.1016/j.jad.2013.10.036. Epub 2013 Oct 29.

PMID:
24268616
12.

Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression.

Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ, Soleimani L, Charney DS, Foulkes AL, Mathew SJ.

Depress Anxiety. 2014 Apr;31(4):335-43. doi: 10.1002/da.22253. Epub 2014 Mar 25.

13.

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.

Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ.

Am J Psychiatry. 2013 Oct;170(10):1134-42. doi: 10.1176/appi.ajp.2013.13030392.

14.

Ketamine as a fast acting antidepressant: current knowledge and open questions.

Salvadore G, Singh JB.

CNS Neurosci Ther. 2013 Jun;19(6):428-36. doi: 10.1111/cns.12103. Epub 2013 Apr 12. Review.

PMID:
23578128
15.

Intravenous ketamine for treatment-resistant major depressive disorder.

Covvey JR, Crawford AN, Lowe DK.

Ann Pharmacother. 2012 Jan;46(1):117-23. doi: 10.1345/aph.1Q371. Epub 2011 Dec 20. Review.

PMID:
22190250
16.

Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV.

Biol Psychiatry. 2013 Aug 15;74(4):250-6. doi: 10.1016/j.biopsych.2012.06.022. Epub 2012 Jul 27.

17.

Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.

Xu AJ, Niciu MJ, Lundin NB, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Machado-Vieira R, Zarate CA Jr.

Neural Plast. 2015;2015:858251. doi: 10.1155/2015/858251. Epub 2015 Jun 7.

18.

Ketamine for treatment-resistant unipolar depression: current evidence.

Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW.

CNS Drugs. 2012 Mar 1;26(3):189-204. doi: 10.2165/11599770-000000000-00000. Review.

19.

[Antidepressant effect of ketamine, a N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, in the therapy of treatment-resistant depression].

Gosek P, Chojnacka M, Bieńkowski P, Swiecicki Ł.

Psychiatr Pol. 2012 Mar-Apr;46(2):283-94. Review. Polish.

PMID:
23214398
20.

The promise of ketamine for treatment-resistant depression: current evidence and future directions.

DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV.

Ann N Y Acad Sci. 2015 May;1345:47-58. doi: 10.1111/nyas.12646. Epub 2015 Feb 3. Review.

Supplemental Content

Support Center